APP and Alzheimer disease: Together, these data show that ADZ3293 can inhibit BACE1 activity and reduce Aβ generation in both AD mouse models, and the differences in sleep disturbances in 5xFAD mice and APP KI mice following AZD3293 treatment is unlikely because of ADZ3293’s inhibition of APP processing.